TickerFacts.

Company research / ALKS

Alkermes plc. (ALKS)

Build a valuation ↗↓ Download CSV

CIK 0001520262 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends around Dec 31

For the year ended 2025-12-31, Alkermes plc. reported revenue of $1.48B. Revenue fell 5.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $1.67B.

Key ratios (year ended 2025-12-31)

86.7%
Gross margin (computed)
17.2%
Operating margin
16.4%
Net margin
13.3%
Return on year-end equity
-5.2%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.67B$1.48B$1.56B$1.66B$1.11B$1.17B$1.04B$1.17B$1.09B$903.37M$745.69M
Cost of Revenue$257.49M$196.46M$245.33M$253.04M$218.07M$197.32M$178.32M$180.38M$176.42M$154.75M$132.12M
Gross Profit (computed)$1.41B$1.28B$1.31B$1.41B$893.73M$976.43M$860.44M$990.56M$917.85M$748.63M$613.57M
R&D Expense$391.04M$323.96M$245.33M$270.81M$272.70M$290.92M$394.59M$512.83M$425.41M$412.89M$387.15M
Operating Income$117.26M$253.96M$420.64M$414.12M-$6.09M$97.75M-$112.43M-$175.48M-$99.13M-$147.90M-$208.66M
Depreciation & Amortization$61.63M$27.16M$28.53M$74.93M$77.86M$78.65M$81.85M$80.41M$103.66M$98.52M$94.26M
EBITDA$178.89M$281.12M$449.17M$489.05M$71.77M$176.40M-$30.57M-$95.07M$4.53M-$49.38M-$114.41M
Net Income$66.12M$241.66M$367.07M$355.76M-$158.27M-$48.17M-$110.86M-$196.62M-$139.31M-$157.94M-$208.44M
EPS (Diluted)n/a$1.43$2.17$2.10-$0.97-$0.29-$0.70n/an/an/an/a
Total Assets$4.39B$2.49B$2.06B$2.14B$1.96B$2.02B$1.95B$1.81B$1.83B$1.80B$1.73B
Total Liabilities$2.58B$667.70M$590.59M$933.54M$920.23M$911.90M$882.75M$719.96M$653.72M$594.42M$516.94M
Long-Term Debt$1.52Bn/an/an/an/an/an/an/an/an/a$283.67M
Shareholders' Equity$1.81B$1.82B$1.46B$1.20B$1.04B$1.11B$1.07B$1.09B$1.17B$1.20B$1.21B
Cash & Equivalents$511.53M$388.57M$291.15M$457.47M$292.47M$337.54M$272.96M$203.77M$266.76M$191.30M$186.38M
Operating Cash Flow$251.18M$520.75M$439.12M$401.35M$21.04M$101.72M$82.84M$72.08M$99.28M$19.19M-$63.80M
Capital Expenditures$29.53M$40.42M$33.48M$48.05M$38.26M$28.02M$42.22M$90.94M$69.43M$51.30M$43.66M
Free Cash Flow$221.65M$480.33M$405.64M$353.31M-$17.21M$73.69M$40.62M-$18.86M$29.85M-$32.11M-$107.46M
Share Repurchasesn/an/a$200.28Mn/an/an/an/an/an/an/an/a
Shares Outstanding167.54M165.61M162.18M166.98M164.38M161.94M159.16M157.78M155.76M154.01M152.43M
Weighted Average Diluted Sharesn/a168.74M169.20M169.73M163.74M164.75M158.80Mn/an/an/an/a
EPS (Basic)n/a$1.47$2.22$2.14-$0.97-$0.30-$0.70n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView